Selling high-performance skincare in the EU or UK is no longer just about formulation. One claim, one active ingredient concentration, or one marketing mistake can push a cosmetic product into medicinal territory and trigger serious regulatory consequences.
Cosmeceutical regulation in the EU and UK draws a hard legal line between cosmetic and medicinal classifications, and brands that misread that line face product withdrawal, enforcement notices, and loss of market access.
This guide will help you understand:
- How cosmeceutical CPSR EU requirements work
- Where the cosmetic vs drug EU boundary sits
- What qualifies as a borderline cosmetic medicinal product
- How active ingredients and medicinal claims affect compliance obligations in both the EU and UK markets
For any brand placing high-performance products on the EU or UK market, this is the compliance foundation on which everything else depends.
Key Takeaways
- “Cosmeceutical” has no legal definition in EU or UK law; every product is classified as either a cosmetic or a medicinal product
- A Cosmetic Product Safety Report (CPSR) is legally required before any cosmetic enters the EU or UK market
- Classification depends on intended purpose, mode of action, ingredient concentration, and marketing claims, all assessed together
- A single medicinal claim across any marketing channel can trigger a product reclassification review
- Cosmeceutical CPSRs typically cost more than standard reports due to active ingredient complexity
- Post-Brexit, the EU and UK require separate Responsible Persons, separate portal notifications, and separate compliance documentation
What Is Cosmeceutical CPSR EU?
A cosmeceutical CPSR (Cosmetic Product Safety Report) is a mandatory safety assessment for cosmetic products with high-performance active ingredients sold in the EU or UK. It keeps the product safe before market launch by reviewing ingredient safety, exposure levels, toxicology data, and compliance.
- “Cosmeceutical” is not a legal category in EU or UK law
- Products are strictly classified as cosmetic or medicinal only
- Covers actives like retinoids, AHAs, peptides, and growth factors
- Higher-risk formulas require deeper toxicology and expert assessment
The CPSR is legally required for all cosmetics before sale, especially for advanced formulations.
Cosmetic vs Drug Classification in EU and UK Law
Cosmetic Product: A cosmetic is defined as a product applied to the outside of the body to clean it, change its appearance, protect it, or keep it in good condition.
Medicinal Product: A medicinal product is one that treats, prevents, or cures a disease, or that changes, restores, or modifies how the body functions. That last phrase, “modifies physiological function”, is where most cosmeceutical brands run into classification problems.
How EU Cosmetic Classification Is Determined
Classification is never based on a single factor. Regulators assess all of the following together:
| Factor | What Regulators Assess |
| Intended purpose | Is the product meant to improve appearance or to treat a condition? |
| Mode of action | Does it work on the surface, or does it change biological function? |
| Active ingredient concentration | Is the dose cosmetic or pharmacologically active? |
| Marketing claims | Do labels, ads, or social content describe disease treatment or biological mechanisms? |
| Packaging presentation | Does the overall presentation suggest a cosmetic or a medicine? |
| Target user group | Is it designed for general consumers or for a specific medical condition? |
A low-strength retinol cream that claims to “reduce the appearance of fine lines” is treated as a cosmetic because it only addresses visible skin improvement.
But the same ingredient at a higher strength, which claims to “stimulates fibroblast activity and reverses photoageing,” goes beyond appearance to explain how it works within the skin. That kind of biological claim can change its legal classification.
In EU/UK rules, ingredients, strength, and marketing claims all work together, not separately.
Cosmetic vs Borderline vs Medicinal Products Explained
The table below shows where real product types sit across the three regulatory zones. Borderline products carry the highest compliance risk and require a formal classification review before going on sale.
| Cosmetic Product | Borderline, Review Required | Medicinal Product |
| Moisturizers and face creams with hydration or protective claims | Retinol above 0.3% in leave-on products (current SCCS threshold) | Prescription-strength retinoids, tretinoin, and isotretinoin, for acne or photoageing |
| SPF sunscreen at cosmetic-grade concentrations | AHA peels at concentrations above standard cosmetic limits | Medicated anti-dandruff shampoos with antifungal actives at therapeutic doses |
| Shampoos and conditioners with general hair care claims | Anti-hair loss serums using the mechanism-of-action or regrowth language | Any product claiming to treat, cure, or prevent a named disease |
| Low-concentration AHA toners with surface exfoliation claims | Skin-lightening products at active concentrations with depigmentation claims | Products containing Active Pharmaceutical Ingredients at pharmacologically active levels |
| Niacinamide serums for brightening or pore appearance | Formulas combining multiple high-concentration actives with biological outcome claims | Hair loss treatments are making clinical regrowth efficacy claims |
| Standard retinol with appearance-based claims | High-dose peptide complexes with cellular repair language | Topical antibiotics or antifungals in skincare format |
Borderline products are not automatically treated as medicines. However, they must go through a clear, documented classification review before being sold. Launching without this review can lead to serious regulatory problems and business risks.
Common Cosmeceutical Products That Trigger Classification Reviews
Include:
- Retinol serums
- Hair growth serums
- Peptide creams
- Acne treatments
- Skin-lightening creams
- Hormonal cosmetics
- CBD skincare
- Stem-cell cosmetics
Borderline Cosmetic Products: Risks and Regulatory Enforcement
Most cosmeceutical enforcement happens in the borderline category. Regulators assess products case by case, reviewing:
- Formula and ingredient pharmacology
- Intended use and target users
- Claims across all marketing channels
UK MHRA and EU authorities review more than labels; they monitor websites, social media, influencer content, and advertising. A product can be legally formulated yet still face reclassification because of its marketing.
Compliance is therefore an ongoing obligation, and a documented borderline assessment completed before launch offers the strongest regulatory protection.
Prohibited Medicinal Claims in EU Cosmetic Regulations
Medicinal claims are not allowed on cosmetics under EU and UK law. Cosmetic claims can only describe visible or appearance-based results, like smoother or brighter skin. Medicinal claims talk about how something changes the body inside, such as cells or body functions, or treats diseases. This rule applies everywhere, including labels, websites, ads, and social media.
| Compliant Cosmetic Claim | Prohibited Medicinal Claim |
| Reduces the appearance of fine lines. | Stimulates collagen synthesis to reverse wrinkles. |
| Brightens skin tone | Inhibits melanin production to treat hyperpigmentation. |
| Soothes sensitive skin. | Reduces inflammatory cytokine response. |
| Strengthens hair fibre. | Treats androgenetic alopecia. |
| Minimises pore appearance. | Regulates sebum production to treat acne. |
| Protects against environmental stress. | Repairs UV-induced DNA damage |
| Hydrates the skin barrier. | Restores epidermal tight junction function |
One prohibited claim in one channel is enough to open a reclassification review. Brands that use biological-mechanism language in influencer briefs, on product pages, or in advertising are creating a compliance risk, even when the formula itself is fully compliant with cosmetic law.
Active Ingredients That Increase CPSR Compliance Risk
When a formula contains active ingredients at meaningful concentrations, the CPSR process becomes considerably more demanding. More data is required, the safety methodology becomes stricter, and the assessor needs more specialist experience.
- Systemic absorption: High-dose retinoids penetrate beyond the outer skin layer. The Systemic Exposure Dosage (SED) calculation must use actual dermal penetration data, not default figures.
- Photosensitivity: AHAs and retinoids require a formal photosensitivity assessment. This is a documented CPSR requirement, not optional.
- Cumulative exposure: Many consumers use multiple active products simultaneously. The combined daily SED from a full skincare routine must be factored into each product’s individual safety assessment.
- Ingredient interactions: Two activities that are each safe on their own may create a higher risk when combined. That interaction must be explicitly documented in the CPSR.
The Margin of Safety (MoS) Calculation
The MoS is the core mathematical calculation inside every CPSR.
MoS = NOAEL ÷ SED
(NOAEL = No Observed Adverse Effect Level from toxicological studies; SED = Systemic Exposure Dosage)
For cosmeceutical formulas, an MoS below 100 requires formal written justification from the assessor. In practice, most qualified assessors will ask for reformulation rather than justify a low MoS for a leave-on product used every day. This calculation requires ingredient-specific toxicological data and professional accountability, which is why template CPSR services cannot produce a legally valid report for cosmeceutical products.
Cosmeceutical CPSR Structure: Part A and Part B
Every cosmeceutical CPSR EU submission must follow the two-part structure set out in Annex I of EC Regulation 1223/2009. Both parts are mandatory. Incomplete data in either section can make the report non-compliant.
| Section | What It Contains | Who Prepares It |
| Part A: Safety Information | Full formula, ingredient properties, physicochemical data, microbiological specs, preservation efficacy, packaging migration data, impurity data, exposure calculations, nanomaterial data if applicable | The brand/formulator collects and submits |
| Part B: Safety Assessment | Toxicological profile per ingredient, MoS calculations, photosensitivity and reproductive toxicity review, overall safety conclusion, assessor’s signed declaration | Qualified safety assessor only |
Part A is the data-gathering section. For cosmeceutical products, it is typically longer and more detailed than for standard cosmetics because of the depth of documentation required for high-concentration activities.
Part B is where the qualified assessor applies their toxicological judgment to everything in Part A. The assessor’s signature on Part B carries full professional liability. A qualified assessor will not sign Part B without complete and accurate Part A data.
Cosmeceutical CPSR Process in the EU and the UK
Step 1: Finalize the Formula Lock the formula completely. Every ingredient must be confirmed by its INCI name and exact percentage concentration.
Step 2: Collect Raw Material Documentation. Get Safety Data Sheets, specification sheets, Certificates of Analysis, and any available toxicological data from every raw material supplier. Nanomaterial suppliers must provide Article 16 documentation.
Step 3: Complete Challenge Testing. Preservation efficacy and microbiological specification data must be produced on the finished formula, not an earlier prototype.
Step 4: Compile Packaging Compatibility Data. The data from packaging materials must be collected. This is especially important for cosmeceuticals in pump or airtight formats.
Step 5: Build Part A. All collected data is compiled into Part A. For cosmeceutical products, this section is more detailed than for standard formulas.
Step 6: Safety Assessor Completes Part B. A qualified assessor reviews all Part A data, runs MoS calculations for each ingredient, assesses photosensitivity and reproductive toxicity where relevant, and signs the safety conclusion under professional liability.
Step 7: CPSR Enters the Product Information File. The completed CPSR is stored in the Product Information File (PIF), held by the Responsible Person and made available to enforcement authorities on request.
Typical timelines:
| Product Type | Estimated Timeline |
| Standard cosmetic | 4 – 8 weeks |
| Cosmeceutical with active ingredients | 8 – 12 weeks |
| Complex formula or incomplete documentation | 12+ weeks |
Preparing complete documentation before commissioning is the most effective way to reduce turnaround time.
Who Can Issue a CPSR in the EU and the UK?
Under EU and UK law, a CPSR can only be issued and signed by a qualified safety assessor with a recognized degree in:
- Pharmacy
- Toxicology
- Medicine
- Related scientific disciplines
For cosmeceutical products, specialist experience is equally important. Assessors with expertise in retinoids, AHAs, peptides, or nanomaterials are better equipped to evaluate complex active formulas. Since the Part B signature carries professional liability, authorities may closely review the assessment for higher-risk or borderline products.
Documents Required for a CPSR Submission
Incomplete documentation is the most common reason CPSR timelines are extended, especially for cosmeceutical products, where assessors often need additional data on high-concentration activities.
Prepare all of the following before commissioning:
- Full quantitative formula with INCI names and exact percentage concentrations
- Safety Data Sheets (SDS) and specification sheets for all raw materials
- Certificate of Analysis (CoA) for each raw material from the specific supplier being used
- Preservation efficacy and challenge test results on the finished formula
- Microbiological specification for the finished product
- Packaging material specifications and available migration data
- Intended use description, application amount, frequency, body area, and target consumer group
- Any existing toxicological or clinical data on the formula or key active ingredients
- Nanomaterial documentation under Article 16, if applicable
Having all of this ready before the assessor begins can significantly reduce assessment time.
CPSR Validity and When Updates Are Required
A CPSR has no fixed expiry date, but it is not a permanent document either. It remains valid only as long as the formula, packaging, intended use, ingredient suppliers, and the toxicological data supporting it stay unchanged.
A CPSR review and update are required when any of the following happen:
| Trigger | Why It Matters |
| Ingredient supplier changes | Safety data is supplier-specific, not ingredient-generic |
| Active ingredient concentration changes | Alters the SED and MoS calculations |
| Product format changes (e.g., serum to cream) | Changes the exposure and absorption profile |
| New ingredient added to the formula | Requires a full toxicological assessment of the new ingredient |
| New SCCS opinion on an existing ingredient | May update the safety basis for that ingredient |
| Intended use or target consumer changes | Changes exposure assumptions in Part A |
For cosmeceutical products, most qualified assessors recommend a proactive review every 2–3 years, even in the absence of formula changes. The SCCS has been particularly active on retinol, AHAs, and certain peptide classes, and a safety assessment that was fully valid three years ago may no longer reflect current regulatory science.
Cosmeceutical CPSR Cost Breakdown
CPSR pricing scales with formula complexity, the number of active ingredients requiring detailed toxicological review, and whether a borderline classification assessment adds an extra layer of evaluation.
| Formula Type | Estimated CPSR Cost (EU/UK) |
| Simple cosmetic, standard ingredients | £200 – £400 |
| Mid-complexity formula, 6 to 15 ingredients | £350 – £650 |
| Cosmeceutical with multiple actives | £650 – £1,200 |
| Borderline product with classification review | £1,000 – £2,000+ |
| Nanomaterial or novel ingredient formula | £1,200 – £2,500+ |
Online CPSR services that charge £50–£100 are usually not compliant. A proper CPSR must be done by a qualified safety assessor who reviews your exact formula, supplier documents, and exposure calculations for your specific product, not a generic template with a changed product name.
Authorities can easily spot weak or fake CPSRs. If a report is invalid, it can lead to product removal, fines, and regulatory action, which usually cost much more than getting a correct CPSR done from the start.
Cosmeceutical Regulation After Brexit: EU vs UK Differences
Since Brexit, the EU and UK operate as parallel but legally separate regulatory frameworks. The core CPSR structure and safety assessment methodology are almost identical, but the administrative requirements differ in ways that matter for brands active in both markets.
| Requirement | EU (EC 1223/2009) | UK (UK Cosmetics Regulation) |
| Responsible Person | EU-based RP required | UK-based RP required |
| Notification portal | CPNP | SCPN |
| Borderline review body | National competent authority | MHRA |
| Nanomaterial notification | Separate EU notification required | A separate UK notification is required |
| CPSR assessor credentials | EU-recognized qualification | UK-recognized qualification |
| Primary enforcement body | National CA + European Commission | OPSS + MHRA |
The formula can be identical across both markets. The compliance infrastructure must be built separately. A brand selling the same retinol serum in Germany and the UK needs a Responsible Person in both jurisdictions, two separate portal notifications, and a CPSR that satisfies assessors credentialed in each market.
Conclusion: Building Compliance Before Market Launch
Cosmeceutical regulation in the EU and UK is precise, well-established, and actively enforced. The cosmetic vs drug EU boundary, borderline cosmetic-medicinal rules, prohibited medicinal claims, and active ingredients CPSR requirements all connect, and a gap in any one area can have consequences across the others.
A properly structured cosmeceutical CPSR EU submission, built on complete Part A data, signed by a qualified assessor, and kept current with SCCS guidance, is not an optional compliance step. It is the legal foundation on which every compliant product stands. Brands that take compliance seriously before launch are better placed to hold their market access, meet regulatory expectations, and protect their customers. Getting it right the first time is almost always less costly than fixing problems after the fact.
FAQ: Cosmeceutical CPSR EU and UK Rules
How long is a CPSR valid for?
A CPSR has no fixed expiry date. However, it must be reviewed whenever the formula, ingredients, packaging, suppliers, or product use changes. For cosmeceutical products, most assessors recommend updating the CPSR every 2–3 years to remain aligned with the latest SCCS safety guidance.
What is the difference between a cosmetic and a drug under EU and UK law?
A cosmetic improves appearance, cleanses, or protects the body’s surface. A medicinal product treats a disease or changes how the body functions. Classification depends on ingredient strength, product purpose, and all marketing claims used across packaging, websites, and advertisements.
What is a CPSR, and who needs one?
A CPSR is a Cosmetic Product Safety Report required for every cosmetic sold in the EU or UK. It confirms the product is safe for use. Any brand selling a cosmetic product must have a valid CPSR completed by a qualified safety assessor before launch.
How much does a cosmeceutical CPSR cost?
A standard cosmetic CPSR usually costs between £200 and £650. Cosmeceutical products with strong active ingredients, nanomaterials, or borderline classification risks may cost £650–£2,500. The final price depends on formula complexity and the amount of safety data required.
How long does a CPSR take?
A standard cosmetic CPSR normally takes 4–8 weeks. Complex cosmeceutical products may take 8–12 weeks or longer, especially if supplier documents are incomplete. Preparing all formulas, testing, and ingredient data before starting helps reduce delays and speeds up approval.
When does a cosmetic product become medicinal?
A cosmetic may become medicinal when it claims to treat a disease or change how the body works. High active ingredient levels, biological claims, disease-related wording, and pharmaceutical ingredients can all increase classification risk. Regulators assess the formula, claims, and marketing together.
